There has been significant progress in the last few years in demonstrating the utility of recombinant viral vectors in treating a variety of ocular diseases. The field has moved beyond 'proof-of-principle' and, in fact, has entered the phase where some of these vectors/paradigms are being or soon will be evaluated in human clinical trials. For this reason and also, to increase the understanding of immunological effects of transgenes/viral vectors on the eye, it is important to summarize what is known about these effects. Here, the biology of and immune responses to intraocular injection of three different recombinant viral vectors -adenovirus, adeno-associated virus (AAV), and lentivirus -are summarized. Perhaps, in part because of the unique immunological environment of the eye, the immunological effects of these viruses appear to be fairly benign. Nevertheless, a significant cell-mediated immune response can develop after intraocular administration of adenovirus. The magnitude of this response is affected by the nature of the intraocular compartment to which this virus is administered. Neither AAV nor lentivirus, however, elicit a cell-mediated response and are thus promising vectors for treatment of chronic ocular (retinal) diseases. Gene Therapy (2003) 10, 977-982.
Introduction
Significant progress in understanding the molecular bases of a variety of forms of ocular diseases has led to the recent development of promising gene therapy techniques for treatment of these diseases. These studies to date have involved application of recombinant viral vectors to spontaneous and genetically engineered animal models of the diseases. The diseases that have been studied are diverse and include retinal degenerative diseases (retinitis pigmentosa, Leber Congenital Amaurosis (LCA)), glaucoma, neovascular diseases (choroidal neovascularization (CNV), diabetic retinopathy, retinopathy of prematurity), cancer (retinoblastoma), and corneal dystrophies. The selection of viral vectors for treatment of these diseases is dictated in large part by the tropism and expression patterns of the vectors and also, by progress in the field of 'vectorology'. As progress in this technology continues, new opportunities arise. One factor that will influence the outcome of gene therapy endeavors is the host immune response to foreign antigens in the vector and/or encoded by the transgene. A nonimmunogenic viral vector is desirable for treatment of chronic diseases. The induction of an inflammatory immune response locally may compromise the stability of long-term transgene expression, and may preclude readministration of the vector. For treatment of acute diseases, a transient inflammatory response may be more tolerable. Nevertheless, since the majority of cell types in the eye are terminally differentiated, a loss of these cells because of inflammation will have long-term consequences with respect to vision. For example, an inflammatory response that kills photoreceptors would be devastating as these cells, which initiate the entire visual process, exit the cell cycle early in life and are thus irreplaceable. Immunological responses in the eye could also have toxic effects on other portions of the nervous system. An inflammatory response targeting retinal ganglion cells, for example, could have serious consequences, as axons from these cells synapse in multiple locations in the brain. Immunological responses in the vitreous/anterior segment of the eye could result in a blockage of the normal flow of intraocular fluids. This, in turn, could result in increased intraocular pressure and glaucoma. Finally, immune-mediated destruction of the cornea would necessitate a cornea transplant.
While most attention in the ocular gene therapy field has been given to studies of potential therapeutic effects, it will not be long before viral vectors are used for other applications -for example, to probe the synaptic contacts of specific retinal cell types or to generate animal models through delivery of reactive RNA molecules or dominant-negative transgenes. Given the particular goals/ requirements of each study and the biological differences in the recombinant viral vectors, it is important to understand the immunological effects that may come into play in various study designs. This review aims to summarize what is known about the immunological effects of three recombinant viral vectors which have been evaluated in studies of the eye: adenovirus, adeno-associated virus (AAV), and lentivirus. (Other viruses, including retrovirus, herpes virus, vaccinia, and baculovirus have been tested for ocular transduction and general inflammatory characteristics. 1, 4 Only adenovirus, AAV, and lentivirus have been studied from immunological perspectives, however.) The cellular transduction characteristics are reviewed first, since this dictates the ocular delivery approach (subretinal injection to target posterior structures versus intravitreal or intracameral injection to target anterior eye structures). This is important as the route of delivery has an impact on the immunological responses.
Discussion
Recombinant viral vectors and ocular cell transduction characteristics Adenovirus. The studies published to date involve use of E1 and E1/E3-deleted adenoviruses and gutted adenoviruses generated on a backbone provided by adenovirus serotype 5. Subretinal injection of these viruses results in efficient transduction of the retinal pigment epithelium (RPE) in adult animals ( Figure 1 ). 5, 6 Photoreceptors of animals with inherited retinal degeneration can be targeted more efficiently than those of animals with wild-type retinas. Occasional Muller cells are also transduced after subretinal injection of recombinant adenovirus. 7 Intravitreal injection of adenovirus results in transduction of Muller cells and a number of anterior segment structures ( Figure 1) . 7 Of these, corneal endothelium, iris pigment epithelium and trabecular meshwork cells are efficiently transduced. 8 Corneal endothelium can also be efficiently transduced through intracameral (into the anterior chamber) injection of adenovirus 8 or through ex vivo exposure of the cornea to this virus. 9, 10 Despite the proximity of the subretinal space to the vitreal cavity, there are marked differences in stability of adenovirus-mediated transduction after administration to the two compartments. High levels of transgene product persist in immune-competent mice after subretinal injection of recombinant adenovirus for at least 1 month and up to 95 days after injection although levels diminish over time. 5, 11 In contrast, although intravitreal or intracameral injection in immune-competent mice results in high levels of transgene expression within 48 h of injection, there is no evidence of expression by 2 weeks after injection. 8 Larkin et al 9 have found similar evidence of short-term expression even after transplantation of corneas infected ex vivo with recombinant adenovirus virus. 10 Adeno-associated virus. AAV serotype 2 (AAV2) has been used successfully and efficiently through subretinal injection to transduce photoreceptors and RPE in a number of gene therapy paradigms. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] This virus also targets ganglion cells efficiently if it is injected intravitreally 26, 27 ( Figure 1 ). AAV2 has not been found, as yet, to target structures in the anterior chamber of the eye. Recently a number of new serotypes of AAV have been identified and capsids of several of these serotypes have been evaluated with respect to their effects on retinal transduction characteristics. For such studies, the genome and ITRs of AAV2 have been packaged in AAV of a different capsid serotype. 28, 29 Thus, AAV2/5 refers to AAV of genome type 2 packaged in an AAV5 capsid. The exchange of capsids has strong effects on transduction characteristics including cellular specificity and onset and efficiency of transgene expression. For example, AAV2/5 targets photoreceptors and RPE cells efficiently ( Figure 1 ) and results in a more rapid onset of transgene expression than AAV2 (1-2 weeks instead of 4-6 weeks in mice); AAV2/1 targets RPE cells and cone photoreceptor cells nearly exclusively after subretinal injection and results in a rapid onset of transgene expression (4 days). 
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With the exception of inner retinal blood vessels, lentivirus does not appear to target any other ocular cell type, even after intravitreal injection. 28 The eye and immune response A feature of the eye which makes it an attractive target for gene therapy is its 'immune privileged' status. The fact that an 'immune deviant' response is elicited in the eye on encounter with antigen has been well documented. Ocular administration of antigen affects the cytokine milieu and the overall immune status of the eye. Most of what is known about the immunological features of the eye derives from anterior chamber injection. The immune-deviant response induced by injection of antigen into the anterior chamber of the eye, a phenomenon known as anterior chamber-associated immune deviation (ACAID), is characterized by suppression of delayed-type hypersensitivity (DTH) and the inability to produce complement-fixing antibodies. 30 Injection of soluble antigen protein into the anterior chamber can also result in an altered cytokine milieu, characterized by downregulation of the proinflammatory cytokine IFN-g, and augmented levels of the immunosuppressive cytokines TGF-b, IL-4, and IL-10. 31 However, particulate or cell-associated antigens may also induce IL-12 and Th1 responses after anterior chamber injection. 32 The posterior part of the eye also appears to have immune deviant features. Streilein et al 30, 33, 34 reported an immune-deviant response against soluble and cell-bound antigens in the subretinal space. This space is able to accept RPE allografts and neonatal ocular tissue and sustain them without induction of a significant DTH response. 33 The anatomical structure of the eye may assist in mediating immune deviation. Much of the eye is avascular and there are a number of cellular and physical barriers which enforce the separation from the blood supply. Apart from the physical barriers, the eye produces a number of molecules that may contribute to its 'immune privilege.' Such molecules include transforming growth factor (TGF-b), [35] [36] [37] melanocyte-stimulating hormone, vasoactive intestinal peptide, calcitonin gene-related peptide (CGRP), 38 Fas ligand, 39 and inhibitors of complement activation and fixation (anterior chamber of the eye). 40, 41 These have been postulated to play a role in inducing different phases of ACAID. 31 Recombinant viral vectors and immunological effects after ocular delivery Adenovirus. Induction of a cell-mediated response can limit transgene expression following adenovirus delivery to the eye. 42, 43 This likely accounts for the transient nature of transgene expression following delivery of this vector (see above). Hoffman et al 42 evaluated the role of cell-mediated immunity in the differences in stability of ocular adenovirus-mediated transgene expression patterns in the posterior and anterior compartments of the eye. These two compartments differ in the degree of inflammation seen after delivery of adenovirus, with a more severe inflammatory response occurring after intravitreal injection. 44 When subretinal injection of recombinant adenovirus was compared in immunecompetent versus immune-deficient (nu/nu) mice, there was no significant difference in stability of expression between the two strains of mice. However, intravitreal injection of this virus led to different results: there was a marked prolongation of transgene expression in the nu/nu mice compared to immune-competent mice. This suggests that there are different immunologic responses to delivery of recombinant adenovirus in the anterior and posterior segments of the eye. Additional studies involving coinjections of CTLA4Ig (which blocks costimulatory signals normally provided by the interaction of ligands on antigen-presenting cells with receptors on T cells 45 ) demonstrated no effect on stability of transgene expression owing to the presence of this immunoglobulin. Proteins have finite stability, however. One method to attain a constant supply of the protein is to deliver the relevant gene through virusmediated transduction. Ali et al 46 reported that local production of CTLA4-Ig through adenovirus-mediated gene transfer, can prolong adenovirally mediated reporter gene expression in the mouse retina. Similarly, cotreatment with other immunosuppressive agents extends transgene expression after intraocular injection of adenovirus. 42, 46, 47 The cellular immune response mediated by adenovirus injection is likely because of the fact that this virus targets APCs. 48 What are the APCs in the eye that are infected by adenovirus? Potential candidates include RPE cells, and dendritic cells in the choroid or retinal microglia . In support of RPE cells as candidates, there is activation of Class II major histocompatability complex (MHC) proteins on RPE cells in retina following subretinal injections in mouse eyes as well as in vitro following adenovirus infection in RPE cell primary cultures. 49 Identification of the set of APCs in the eye could give a clue as to the mechanisms by which the cell-mediated response after intraocular injection differs from that typically induced by systemic application of adenovirus. Relevant to the cellular immune response data, there is no report of cellular infiltrate in the subretinal space after accurate injection of recombinant adenovirus, although macrophages are often observed. 5, 11, 42, 50 Cellular infiltrate is occasionally observed after adenovirus injection in other ocular sites, however (the vitreal cavity, for instance). 44 This suggests that immune response to recombinant adenovirus can lead to clearance of the virus and/or transduced cells. Evaluation of the humoral response to adenovirus after intraocular delivery in mice has shown that this virus can induce a systemic humoral response that is suppressed, in comparison to the response after intradermal injection. Subretinal injection of adenovirus elicits a predominant Th2 response (characterized by high levels of IgG2b and IgG3). Subretinal adenovirus injections also induced weaker levels of IgG2a. The responses are reversed after intradermal injection of adenovirus, where a predominant Th1 response (with increased IgG2a levels) is found. The contrast in immune response following subretinal (Th2) and systemic (Th1) exposure of adenovirus lends support to the notion that the subretinal space induces immune deviation. 49 Additional support for immune deviation of the subretinal space comes from experiments evaluating suppression of DTH. DTH towards viral proteins and GFP is suppressed after subretinal injection with adenovirus. This is in marked contrast to the results of intradermal injection. The reversal of DTH after subretinal delivery suggests that a suppressor T-cell population is generated Immune response to intraocular delivery of viral vectors J Bennett after injection of adenovirus in this location and that this T-cell population downregulates the cytotoxic T cell reaction mediating the DTH response. Finally, additional evidence of immune deviance of the subretinal space was furnished by observation that adoptive transfer of T cells in mice that had been subretinally injected with adenovirus, conferred immunosuppressive properties on the naive mice. The transferred T cells protect these animals from proinflammatory responses and allow prolonged transgene expression. 49 Recently, two phase 1 human clinical trials have been approved which involve injection of recombinant adenovirus to the vitreous. Hurwitz et al 51 have initiated a 'suicide' gene therapy program involving recombinant adenovirus targeted at retinoblastoma. Rasmussen et al 52 recently received approval for a gene therapy program targeting the 'wet' form of AMD. Data resulting from the effects of adenovirus delivery in these eyes will add to our understanding of the nature of the ocular immunological response with respect to these vectors. Importantly, however, these may not be the same responses seen in a healthy eye which has intact immunological barriers.
Adeno-associated virus. AAV is a human parvovirus, which has not been associated with any human disease. 53 This vector has favorable immunologic characteristics, as recombinants are deleted of all viral open reading frames retaining only the inverted terminal repeat sequences (ITRs). 54 Exposure to recombinant AAV has not been reported to induce a cell-mediated immune response in the eye or elsewhere in the body. After intraocular delivery of AAV, there is suppression of DTH, but an induction of IgG1 and IgG2b (Th2-type) antibodies. 26, 27, 49 This appears at least in part because of the fact that AAV does not transduce APCs. 48 This virus can, however, induce a strong antibody response directed at both viral antigens and the transgene. [25] [26] [27] Antibodies are detected in intraocular fluid (anterior chamber fluid and vitreous) as well as in serum. Nevertheless, the immune response following intraocular injection of AAV is similar to that described in ACAID (ie, a predominant Th2 like response). [25] [26] [27] 55 One question relating to the AAV-induced humoral response is whether it would be possible to readminister the virus/transgene in the presence of virus-specific antibodies. Studies in mice and in monkeys have demonstrated that these antibodies are not neutralizing and that it is possible to obtain additional transduction events. 56, 57 Owing to its favorable immunological characteristics and because it targets particular ocular cell types efficiently and in a stable fashion, this virus is an excellent candidate for future ocular gene therapy human clinical trials.
Lentivirus. After intraocular injection of lentivirus,
there is little inflammation and, when the virus is exposed to the subretinal space, transgene expression initiates soon after injection. 28 With lentiviral vectors, an additional reason to characterize the inflammatory/ immune response is that the deleterious immunological effects of its parental virus, HIV, have been well documented. It is not known whether recombinant lentiviral vectors differ from the wild-type vectors in these responses.
A recent study of Karakousis et al 58 characterized the pattern of cytokine induction following subretinal injection of a VSVG-enveloped lentivirus carrying a cytomegalovirus-driven enhanced green fluorescent protein (EGFP) cDNA. Animals injected subretinally showed significant induction of the Th2 cytokines IL-4, IL-10, and TGF-b. Following subretinal injection of recombinant lentivirus, both IgG1 and IgG2b antibody isotypes were induced, also reflecting a Th2-type immune response. In addition, neutralizing antibodies were not formed, as judged by in vitro assays. Consistent with these results, inflammatory cells were not apparent in injected retinal tissue upon immunohistochemical examination. 58 In summary, subretinal administration of lentivirus induces an immune-deviant response. This process may pertain to characteristics of this virus and/or may be mediated by the RPE cells, which are the target cells of lentiviral transduction. RPE cells may serve as antigen-presenting cells, processing and presenting viral antigen in an immune-deviant fashion, perhaps under the influence of immunosuppressive cytokines.
Conclusions
Viral vectors are useful reagents not only for delivering therapeutic molecules, but also for deciphering the nature of ocular 'immune privilege.' There are practical reasons to consider the immunological consequences of virus delivery to the human eye given the progress in gene therapy applications to treat a diverse set of ocular diseases in animal models. Ultimately, a number of these paradigms will be tested in human clinical trials. With continued improvements in viral vector technology, it will also become possible to elucidate the cellular and immunological reactions, which control the response of the eye to foreign molecules. This information may have practical consequences not only for developing treatments of inflammatory eye disease, but also for information that may assist in modulating systemic inflammatory reactions.
